1
|
Yang Z, Xiao D, Ling KHJ, Tarnowski T, Humeniuk R, Parmentier B, Fu YHA, Johnson E, Luna ML, Goudarzi H, Cheng Q. The determination of Sulfobutylether β-Cyclodextrin Sodium (SBECD) by LC-MS/MS and its application in remdesivir pharmacokinetics study for pediatric patients. J Pharm Biomed Anal 2022; 212:114646. [PMID: 35180564 DOI: 10.1016/j.jpba.2022.114646] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 02/02/2022] [Accepted: 02/04/2022] [Indexed: 11/29/2022]
Abstract
SBECD (Captisol®) with an average degree of substitution of 6.5 sulfobutylether functional groups (SBE = 6.5), is a solubility enhancer for remdesivir (RDV) and a major component in Veklury, which was approved by FDA for the treatment of patients with COVID-19 over 12 years old and weighing over 40 kg who require hospitalization. SBECD is cleared mainly by renal filtration, thus, potential accumulation of SBECD in the human body is a concern for patients dosed with Veklury with compromised renal function. An LC-MS/MS method was developed and validated for specific, accurate, and precise determination of SBECD concentrations in human plasma. In this method, the hexa-substituted species, SBE6, was selected for SBECD quantification, and the mass transition from its dicharged molecular ion [(M-2H)/2]2-, Molecular (parent) Ion (Q1)/Molecular (parent) Ion (Q3) of m/z 974.7/974.7, was selected for quantitative analysis of SBECD. Captisol-G (SBE-γ-CD, SBE = 3) was chosen as the internal standard. With 25 µL of formic-acid-treated sample and with a calibration range of 10.0-1000 µg/mL, the method was validated with respect to pre-established criteria based on regulatory guidelines and was applied to determine SBECD levels in plasma samples collected from pediatric patients during RDV clinical studies.
Collapse
Affiliation(s)
- Zhengdong Yang
- Department of Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA; Department of Chemistry, University of California, Riverside, CA, USA
| | - Deqing Xiao
- Department of Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA.
| | | | - Thomas Tarnowski
- Department of Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA
| | - Rita Humeniuk
- Department of Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA
| | | | - Yu-Hui Ann Fu
- KCAS Bioanalytical & Biomarker Services, Shawnee, KS, USA
| | - Eric Johnson
- KCAS Bioanalytical & Biomarker Services, Shawnee, KS, USA
| | - Marsha L Luna
- KCAS Bioanalytical & Biomarker Services, Shawnee, KS, USA
| | | | - Quan Cheng
- Department of Chemistry, University of California, Riverside, CA, USA
| |
Collapse
|
2
|
Strege MA, Huang S, Risley DS. Quantitative determination of beta-cyclodextrin in a powder insulin formulation for nasal delivery using hydrophilic interaction chromatography with evaporative light scattering detection. J LIQ CHROMATOGR R T 2019. [DOI: 10.1080/10826076.2019.1571508] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Mark A. Strege
- Bioproducts Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN USA
| | - Siyuan Huang
- Small Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Donald S. Risley
- Small Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| |
Collapse
|